^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Jazz Pharmace
^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Protocol 150-
^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Table 9.2.1.3
^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Primary Effic
^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}(Modified Ful

                      The Mixed Procedure

                       Model Information

     Data Set                     WORK.DBRW_DATA           
     Dependent Variable           CHG                      
     Covariance Structure         Unstructured             
     Subject Effect               id                       
     Estimation Method            REML                     
     Residual Variance Method     None                     
     Fixed Effects SE Method      Kenward-Roger            
     Degrees of Freedom Method    Kenward-Roger            


 
 
 
 
 
 
 
 
 
^S={}CAPS-5: Clinician Administered PTSD Scale; CAPS-5 total sco
^S={}Note:The Modified Full Analysis Set includes all participan
^S={}Note: The baseline (Day -1) value is generally defined as t
^S={}Note:The CAPS-5 total score is the sum of the 20 item-score
^S={}Note: All ICEs are addressed using the treatment policy str
^S={}Note: The LS means, SEs,LS Mean Diff, 95% (CI) and p-value 
^S={}Note: The randomization stratification factor will be remov
^S={}PROGRAM NAME: C:\SASData\JZP-150\150-201\stat\csr_dryrun1\p
^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Jazz Pharmace
^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Protocol 150-
^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Table 9.2.1.3
^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Primary Effic
^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}(Modified Ful

                      The Mixed Procedure

                    Class Level Information
 
      Class       Levels    Values

      id              24    10631001 10631002 11601006    
                            13031001 13991002 13991004    
                            13991007 13991009 16591006    
                            17601002 17601003 17601005    
                            17601007 17601012 17601014    
                            17661002 17661004 19731001    
                            19731002 19731006 19831001    
                            19831005 19831008 19901003    
      AVISITN          2    4 12                          
      trtn             3    1 2 3                         
      SSNRISN          2    1 2                           
      VISITTYN         1    1                             
      wk12             2    0 1                           
 
 
 
 
^S={}CAPS-5: Clinician Administered PTSD Scale; CAPS-5 total sco
^S={}Note:The Modified Full Analysis Set includes all participan
^S={}Note: The baseline (Day -1) value is generally defined as t
^S={}Note:The CAPS-5 total score is the sum of the 20 item-score
^S={}Note: All ICEs are addressed using the treatment policy str
^S={}Note: The LS means, SEs,LS Mean Diff, 95% (CI) and p-value 
^S={}Note: The randomization stratification factor will be remov
^S={}PROGRAM NAME: C:\SASData\JZP-150\150-201\stat\csr_dryrun1\p
^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Jazz Pharmace
^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Protocol 150-
^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Table 9.2.1.3
^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Primary Effic
^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}(Modified Ful

                      The Mixed Procedure

                          Dimensions

              Covariance Parameters             3
              Columns in X                     28
              Columns in Z                      0
              Subjects                         24
              Max Obs per Subject               2


                    Number of Observations

          Number of Observations Read              47
          Number of Observations Used              47
          Number of Observations Not Used           0


 
 
 
 
 
^S={}CAPS-5: Clinician Administered PTSD Scale; CAPS-5 total sco
^S={}Note:The Modified Full Analysis Set includes all participan
^S={}Note: The baseline (Day -1) value is generally defined as t
^S={}Note:The CAPS-5 total score is the sum of the 20 item-score
^S={}Note: All ICEs are addressed using the treatment policy str
^S={}Note: The LS means, SEs,LS Mean Diff, 95% (CI) and p-value 
^S={}Note: The randomization stratification factor will be remov
^S={}PROGRAM NAME: C:\SASData\JZP-150\150-201\stat\csr_dryrun1\p
^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Jazz Pharmace
^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Protocol 150-
^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Table 9.2.1.3
^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Primary Effic
^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}(Modified Ful

                      The Mixed Procedure

                       Iteration History
 
  Iteration    Evaluations    -2 Res Log Like       Criterion

          0              1       319.92747119                
          1              2       311.76051398      0.00000278
          2              1       311.76017581      0.00000000


                   Convergence criteria met.                    


                Covariance Parameter Estimates
 
                Cov Parm    Subject    Estimate

                UN(1,1)     id           140.13
                UN(2,1)     id          77.8997
                UN(2,2)     id           119.41
 
 
^S={}CAPS-5: Clinician Administered PTSD Scale; CAPS-5 total sco
^S={}Note:The Modified Full Analysis Set includes all participan
^S={}Note: The baseline (Day -1) value is generally defined as t
^S={}Note:The CAPS-5 total score is the sum of the 20 item-score
^S={}Note: All ICEs are addressed using the treatment policy str
^S={}Note: The LS means, SEs,LS Mean Diff, 95% (CI) and p-value 
^S={}Note: The randomization stratification factor will be remov
^S={}PROGRAM NAME: C:\SASData\JZP-150\150-201\stat\csr_dryrun1\p
^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Jazz Pharmace
^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Protocol 150-
^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Table 9.2.1.3
^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Primary Effic
^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}(Modified Ful

                      The Mixed Procedure

                        Fit Statistics

             -2 Res Log Likelihood           311.8
             AIC (Smaller is Better)         317.8
             AICC (Smaller is Better)        318.5
             BIC (Smaller is Better)         321.3


                Null Model Likelihood Ratio Test
 
                  DF    Chi-Square      Pr > ChiSq

                   2          8.17          0.0168


 
 
 
 
 
 
^S={}CAPS-5: Clinician Administered PTSD Scale; CAPS-5 total sco
^S={}Note:The Modified Full Analysis Set includes all participan
^S={}Note: The baseline (Day -1) value is generally defined as t
^S={}Note:The CAPS-5 total score is the sum of the 20 item-score
^S={}Note: All ICEs are addressed using the treatment policy str
^S={}Note: The LS means, SEs,LS Mean Diff, 95% (CI) and p-value 
^S={}Note: The randomization stratification factor will be remov
^S={}PROGRAM NAME: C:\SASData\JZP-150\150-201\stat\csr_dryrun1\p
^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Jazz Pharmace
^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Protocol 150-
^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Table 9.2.1.3
^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Primary Effic
^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}(Modified Ful

                      The Mixed Procedure

                 Type 3 Tests of Fixed Effects
 
                           Num     Den
    Effect                  DF      DF    F Value    Pr > F

    BASE                     1    18.5       2.41    0.1377
    trtn                     2    18.6       0.29    0.7502
    wk12                     1    18.8       1.66    0.2138
    SSNRISN                  1    18.6       0.12    0.7294
    BASE*wk12                1    18.8       0.29    0.5943
    trtn*VISITTYN            0                             
    trtn*wk12                2      19       0.37    0.6939
    VISITTYN*wk12            0                             
    trtn*VISITTYN*wk12       0                             


 
 
 
 
 
^S={}CAPS-5: Clinician Administered PTSD Scale; CAPS-5 total sco
^S={}Note:The Modified Full Analysis Set includes all participan
^S={}Note: The baseline (Day -1) value is generally defined as t
^S={}Note:The CAPS-5 total score is the sum of the 20 item-score
^S={}Note: All ICEs are addressed using the treatment policy str
^S={}Note: The LS means, SEs,LS Mean Diff, 95% (CI) and p-value 
^S={}Note: The randomization stratification factor will be remov
^S={}PROGRAM NAME: C:\SASData\JZP-150\150-201\stat\csr_dryrun1\p
^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Jazz Pharmace
^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Protocol 150-
^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Table 9.2.1.3
^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Primary Effic
^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}(Modified Ful

                      The Mixed Procedure

                      Least Squares Means
 
                     Subject'
                     s type
                     of visit            Standard
Effect         trtn  (N)       Estimate     Error    DF  t Value

trtn*VISITTYN  1     1         -14.9449    4.5092  18.4    -3.31
trtn*VISITTYN  2     1         -15.4100    4.5599  18.7    -3.38
trtn*VISITTYN  3     1         -18.5840    4.5612  18.5    -4.07

                      Least Squares Means
 
                            Subject'
                            s type
                            of visit
       Effect         trtn  (N)       Pr > |t|     Alpha

       trtn*VISITTYN  1     1           0.0038      0.05
       trtn*VISITTYN  2     1           0.0032      0.05
 
^S={}CAPS-5: Clinician Administered PTSD Scale; CAPS-5 total sco
^S={}Note:The Modified Full Analysis Set includes all participan
^S={}Note: The baseline (Day -1) value is generally defined as t
^S={}Note:The CAPS-5 total score is the sum of the 20 item-score
^S={}Note: All ICEs are addressed using the treatment policy str
^S={}Note: The LS means, SEs,LS Mean Diff, 95% (CI) and p-value 
^S={}Note: The randomization stratification factor will be remov
^S={}PROGRAM NAME: C:\SASData\JZP-150\150-201\stat\csr_dryrun1\p
^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Jazz Pharmace
^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Protocol 150-
^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Table 9.2.1.3
^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Primary Effic
^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}(Modified Ful

                      The Mixed Procedure

                      Least Squares Means
 
                            Subject'
                            s type
                            of visit
       Effect         trtn  (N)       Pr > |t|     Alpha

       trtn*VISITTYN  3     1           0.0007      0.05

                      Least Squares Means
 
                           Subject'
                           s type
                           of visit
      Effect         trtn  (N)          Lower       Upper

      trtn*VISITTYN  1     1         -24.4044     -5.4854
      trtn*VISITTYN  2     1         -24.9632     -5.8568
      trtn*VISITTYN  3     1         -28.1481     -9.0198
 
 
^S={}CAPS-5: Clinician Administered PTSD Scale; CAPS-5 total sco
^S={}Note:The Modified Full Analysis Set includes all participan
^S={}Note: The baseline (Day -1) value is generally defined as t
^S={}Note:The CAPS-5 total score is the sum of the 20 item-score
^S={}Note: All ICEs are addressed using the treatment policy str
^S={}Note: The LS means, SEs,LS Mean Diff, 95% (CI) and p-value 
^S={}Note: The randomization stratification factor will be remov
^S={}PROGRAM NAME: C:\SASData\JZP-150\150-201\stat\csr_dryrun1\p
^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Jazz Pharmace
^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Protocol 150-
^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Table 9.2.1.3
^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Primary Effic
^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}(Modified Ful

                      The Mixed Procedure

                       Model Information

     Data Set                     WORK.DBRW_DATA           
     Dependent Variable           CHG                      
     Covariance Structure         Unstructured             
     Subject Effect               id                       
     Estimation Method            REML                     
     Residual Variance Method     None                     
     Fixed Effects SE Method      Kenward-Roger            
     Degrees of Freedom Method    Kenward-Roger            


 
 
 
 
 
 
 
 
 
^S={}CAPS-5: Clinician Administered PTSD Scale; CAPS-5 total sco
^S={}Note:The Modified Full Analysis Set includes all participan
^S={}Note: The baseline (Day -1) value is generally defined as t
^S={}Note:The CAPS-5 total score is the sum of the 20 item-score
^S={}Note: All ICEs are addressed using the treatment policy str
^S={}Note: The LS means, SEs,LS Mean Diff, 95% (CI) and p-value 
^S={}Note: The randomization stratification factor will be remov
^S={}PROGRAM NAME: C:\SASData\JZP-150\150-201\stat\csr_dryrun1\p
^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Jazz Pharmace
^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Protocol 150-
^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Table 9.2.1.3
^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Primary Effic
^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}(Modified Ful

                      The Mixed Procedure

                    Class Level Information
 
      Class       Levels    Values

      id              16    10631001 10631002 11601006    
                            13031001 13991002 13991004    
                            13991007 13991009 17601005    
                            17601007 17601014 17661004    
                            19731002 19731006 19831001    
                            19901003                      
      AVISITN          2    4 12                          
      SSNRISN1         2    0 1                           


                          Dimensions

              Covariance Parameters             3
              Columns in X                     12
              Columns in Z                      0
              Subjects                         16
 
^S={}CAPS-5: Clinician Administered PTSD Scale; CAPS-5 total sco
^S={}Note:The Modified Full Analysis Set includes all participan
^S={}Note: The baseline (Day -1) value is generally defined as t
^S={}Note:The CAPS-5 total score is the sum of the 20 item-score
^S={}Note: All ICEs are addressed using the treatment policy str
^S={}Note: The LS means, SEs,LS Mean Diff, 95% (CI) and p-value 
^S={}Note: The randomization stratification factor will be remov
^S={}PROGRAM NAME: C:\SASData\JZP-150\150-201\stat\csr_dryrun1\p
^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Jazz Pharmace
^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Protocol 150-
^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Table 9.2.1.3
^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Primary Effic
^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}(Modified Ful

                      The Mixed Procedure

                          Dimensions

              Max Obs per Subject               2


                    Number of Observations

          Number of Observations Read              37
          Number of Observations Used              32
          Number of Observations Not Used           5


                       Iteration History
 
  Iteration    Evaluations    -2 Res Log Like       Criterion

          0              1       216.28474738                
          1              2       210.12139139      0.00000000
 
 
 
^S={}CAPS-5: Clinician Administered PTSD Scale; CAPS-5 total sco
^S={}Note:The Modified Full Analysis Set includes all participan
^S={}Note: The baseline (Day -1) value is generally defined as t
^S={}Note:The CAPS-5 total score is the sum of the 20 item-score
^S={}Note: All ICEs are addressed using the treatment policy str
^S={}Note: The LS means, SEs,LS Mean Diff, 95% (CI) and p-value 
^S={}Note: The randomization stratification factor will be remov
^S={}PROGRAM NAME: C:\SASData\JZP-150\150-201\stat\csr_dryrun1\p
^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Jazz Pharmace
^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Protocol 150-
^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Table 9.2.1.3
^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Primary Effic
^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}(Modified Ful

                      The Mixed Procedure

                   Convergence criteria met.                    


                Covariance Parameter Estimates
 
                Cov Parm    Subject    Estimate

                UN(1,1)     id           140.06
                UN(2,1)     id          83.1197
                UN(2,2)     id           128.70


                        Fit Statistics

             -2 Res Log Likelihood           210.1
             AIC (Smaller is Better)         216.1
             AICC (Smaller is Better)        217.3
             BIC (Smaller is Better)         218.4
 
 
 
^S={}CAPS-5: Clinician Administered PTSD Scale; CAPS-5 total sco
^S={}Note:The Modified Full Analysis Set includes all participan
^S={}Note: The baseline (Day -1) value is generally defined as t
^S={}Note:The CAPS-5 total score is the sum of the 20 item-score
^S={}Note: All ICEs are addressed using the treatment policy str
^S={}Note: The LS means, SEs,LS Mean Diff, 95% (CI) and p-value 
^S={}Note: The randomization stratification factor will be remov
^S={}PROGRAM NAME: C:\SASData\JZP-150\150-201\stat\csr_dryrun1\p
^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Jazz Pharmace
^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Protocol 150-
^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Table 9.2.1.3
^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Primary Effic
^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}(Modified Ful

                      The Mixed Procedure

                Null Model Likelihood Ratio Test
 
                  DF    Chi-Square      Pr > ChiSq

                   2          6.16          0.0459


                 Type 3 Tests of Fixed Effects
 
                            Num     Den
   Effect                    DF      DF    F Value    Pr > F

   BASE                       1    12.7       1.82    0.2012
   trtn1                      0                             
   wk12                       0                             
   SSNRISN1                   1      12       0.35    0.5646
   VISITTYN1                  0                             
   BASE*wk12                  1      13       0.05    0.8205
   trtn1*VISITTYN1            0                             
   trtn1*wk12                 0                             
 
^S={}CAPS-5: Clinician Administered PTSD Scale; CAPS-5 total sco
^S={}Note:The Modified Full Analysis Set includes all participan
^S={}Note: The baseline (Day -1) value is generally defined as t
^S={}Note:The CAPS-5 total score is the sum of the 20 item-score
^S={}Note: All ICEs are addressed using the treatment policy str
^S={}Note: The LS means, SEs,LS Mean Diff, 95% (CI) and p-value 
^S={}Note: The randomization stratification factor will be remov
^S={}PROGRAM NAME: C:\SASData\JZP-150\150-201\stat\csr_dryrun1\p
^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Jazz Pharmace
^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Protocol 150-
^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Table 9.2.1.3
^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Primary Effic
^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}(Modified Ful

                      The Mixed Procedure

                 Type 3 Tests of Fixed Effects
 
                            Num     Den
   Effect                    DF      DF    F Value    Pr > F

   wk12*VISITTYN1             0                             
   trtn1*wk12*VISITTYN1       0                             


                           Estimates
 
                              Standard
Label               Estimate     Error    DF  t Value  Pr > |t|

1 ACT-PBO  Week 4     5.4114    6.3613  12.4     0.85    0.4110
2 ACT-PBO  Week 4    Non-est                                   
1 ACT-PBO  Week 12    1.6377    6.1032  12.3     0.27    0.7929
2 ACT-PBO  Week 12   Non-est                                   

 
 
^S={}CAPS-5: Clinician Administered PTSD Scale; CAPS-5 total sco
^S={}Note:The Modified Full Analysis Set includes all participan
^S={}Note: The baseline (Day -1) value is generally defined as t
^S={}Note:The CAPS-5 total score is the sum of the 20 item-score
^S={}Note: All ICEs are addressed using the treatment policy str
^S={}Note: The LS means, SEs,LS Mean Diff, 95% (CI) and p-value 
^S={}Note: The randomization stratification factor will be remov
^S={}PROGRAM NAME: C:\SASData\JZP-150\150-201\stat\csr_dryrun1\p
^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Jazz Pharmace
^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Protocol 150-
^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Table 9.2.1.3
^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Primary Effic
^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}(Modified Ful

                      The Mixed Procedure

                           Estimates
 
       Label                Alpha       Lower       Upper

       1 ACT-PBO  Week 4     0.05     -8.3940     19.2168
       2 ACT-PBO  Week 4                                 
       1 ACT-PBO  Week 12    0.05    -11.6219     14.8972
       2 ACT-PBO  Week 12                                


                           Contrasts
 
                                           Num    Den
 Label                                      DF     DF   F Value

 Treatment*Week 4*Subgroup Interaction                         
 Treatment*Week 12*Subgroup Interaction                        

 
 
 
^S={}CAPS-5: Clinician Administered PTSD Scale; CAPS-5 total sco
^S={}Note:The Modified Full Analysis Set includes all participan
^S={}Note: The baseline (Day -1) value is generally defined as t
^S={}Note:The CAPS-5 total score is the sum of the 20 item-score
^S={}Note: All ICEs are addressed using the treatment policy str
^S={}Note: The LS means, SEs,LS Mean Diff, 95% (CI) and p-value 
^S={}Note: The randomization stratification factor will be remov
^S={}PROGRAM NAME: C:\SASData\JZP-150\150-201\stat\csr_dryrun1\p
^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Jazz Pharmace
^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Protocol 150-
^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Table 9.2.1.3
^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Primary Effic
^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}(Modified Ful

                      The Mixed Procedure

                           Contrasts
 
        Label                                    Pr > F

        Treatment*Week 4*Subgroup Interaction          
        Treatment*Week 12*Subgroup Interaction         
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
^S={}CAPS-5: Clinician Administered PTSD Scale; CAPS-5 total sco
^S={}Note:The Modified Full Analysis Set includes all participan
^S={}Note: The baseline (Day -1) value is generally defined as t
^S={}Note:The CAPS-5 total score is the sum of the 20 item-score
^S={}Note: All ICEs are addressed using the treatment policy str
^S={}Note: The LS means, SEs,LS Mean Diff, 95% (CI) and p-value 
^S={}Note: The randomization stratification factor will be remov
^S={}PROGRAM NAME: C:\SASData\JZP-150\150-201\stat\csr_dryrun1\p
^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Jazz Pharmace
^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Protocol 150-
^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Table 9.2.1.3
^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Primary Effic
^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}(Modified Ful

                      The Mixed Procedure

                       Model Information

     Data Set                     WORK.DBRW_DATA           
     Dependent Variable           CHG                      
     Covariance Structure         Unstructured             
     Subject Effect               id                       
     Estimation Method            REML                     
     Residual Variance Method     None                     
     Fixed Effects SE Method      Kenward-Roger            
     Degrees of Freedom Method    Kenward-Roger            


 
 
 
 
 
 
 
 
 
^S={}CAPS-5: Clinician Administered PTSD Scale; CAPS-5 total sco
^S={}Note:The Modified Full Analysis Set includes all participan
^S={}Note: The baseline (Day -1) value is generally defined as t
^S={}Note:The CAPS-5 total score is the sum of the 20 item-score
^S={}Note: All ICEs are addressed using the treatment policy str
^S={}Note: The LS means, SEs,LS Mean Diff, 95% (CI) and p-value 
^S={}Note: The randomization stratification factor will be remov
^S={}PROGRAM NAME: C:\SASData\JZP-150\150-201\stat\csr_dryrun1\p
^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Jazz Pharmace
^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Protocol 150-
^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Table 9.2.1.3
^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Primary Effic
^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}(Modified Ful

                      The Mixed Procedure

                    Class Level Information
 
      Class       Levels    Values

      id              17    10631001 11601006 13031001    
                            16591006 17601002 17601003    
                            17601007 17601012 17661002    
                            17661004 19731001 19731002    
                            19731006 19831001 19831005    
                            19831008 19901003             
      AVISITN          2    4 12                          
      SSNRISN1         2    0 1                           


                          Dimensions

              Covariance Parameters             3
              Columns in X                     12
              Columns in Z                      0
              Subjects                         17
 
^S={}CAPS-5: Clinician Administered PTSD Scale; CAPS-5 total sco
^S={}Note:The Modified Full Analysis Set includes all participan
^S={}Note: The baseline (Day -1) value is generally defined as t
^S={}Note:The CAPS-5 total score is the sum of the 20 item-score
^S={}Note: All ICEs are addressed using the treatment policy str
^S={}Note: The LS means, SEs,LS Mean Diff, 95% (CI) and p-value 
^S={}Note: The randomization stratification factor will be remov
^S={}PROGRAM NAME: C:\SASData\JZP-150\150-201\stat\csr_dryrun1\p
^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Jazz Pharmace
^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Protocol 150-
^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Table 9.2.1.3
^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Primary Effic
^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}(Modified Ful

                      The Mixed Procedure

                          Dimensions

              Max Obs per Subject               2


                    Number of Observations

          Number of Observations Read              44
          Number of Observations Used              33
          Number of Observations Not Used          11


                       Iteration History
 
  Iteration    Evaluations    -2 Res Log Like       Criterion

          0              1       225.77294221                
          1              2       213.63817478      0.00011908
          2              1       213.62783684      0.00000067
 
 
^S={}CAPS-5: Clinician Administered PTSD Scale; CAPS-5 total sco
^S={}Note:The Modified Full Analysis Set includes all participan
^S={}Note: The baseline (Day -1) value is generally defined as t
^S={}Note:The CAPS-5 total score is the sum of the 20 item-score
^S={}Note: All ICEs are addressed using the treatment policy str
^S={}Note: The LS means, SEs,LS Mean Diff, 95% (CI) and p-value 
^S={}Note: The randomization stratification factor will be remov
^S={}PROGRAM NAME: C:\SASData\JZP-150\150-201\stat\csr_dryrun1\p
^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Jazz Pharmace
^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Protocol 150-
^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Table 9.2.1.3
^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Primary Effic
^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}(Modified Ful

                      The Mixed Procedure

                       Iteration History
 
  Iteration    Evaluations    -2 Res Log Like       Criterion

          3              1       213.62778118      0.00000000


                   Convergence criteria met.                    


                Covariance Parameter Estimates
 
                Cov Parm    Subject    Estimate

                UN(1,1)     id           178.20
                UN(2,1)     id           123.28
                UN(2,2)     id           136.44
 
 
 
 
^S={}CAPS-5: Clinician Administered PTSD Scale; CAPS-5 total sco
^S={}Note:The Modified Full Analysis Set includes all participan
^S={}Note: The baseline (Day -1) value is generally defined as t
^S={}Note:The CAPS-5 total score is the sum of the 20 item-score
^S={}Note: All ICEs are addressed using the treatment policy str
^S={}Note: The LS means, SEs,LS Mean Diff, 95% (CI) and p-value 
^S={}Note: The randomization stratification factor will be remov
^S={}PROGRAM NAME: C:\SASData\JZP-150\150-201\stat\csr_dryrun1\p
^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Jazz Pharmace
^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Protocol 150-
^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Table 9.2.1.3
^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Primary Effic
^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}(Modified Ful

                      The Mixed Procedure

                        Fit Statistics

             -2 Res Log Likelihood           213.6
             AIC (Smaller is Better)         219.6
             AICC (Smaller is Better)        220.7
             BIC (Smaller is Better)         222.1


                Null Model Likelihood Ratio Test
 
                  DF    Chi-Square      Pr > ChiSq

                   2         12.15          0.0023


 
 
 
 
 
 
^S={}CAPS-5: Clinician Administered PTSD Scale; CAPS-5 total sco
^S={}Note:The Modified Full Analysis Set includes all participan
^S={}Note: The baseline (Day -1) value is generally defined as t
^S={}Note:The CAPS-5 total score is the sum of the 20 item-score
^S={}Note: All ICEs are addressed using the treatment policy str
^S={}Note: The LS means, SEs,LS Mean Diff, 95% (CI) and p-value 
^S={}Note: The randomization stratification factor will be remov
^S={}PROGRAM NAME: C:\SASData\JZP-150\150-201\stat\csr_dryrun1\p
^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Jazz Pharmace
^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Protocol 150-
^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Table 9.2.1.3
^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Primary Effic
^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}(Modified Ful

                      The Mixed Procedure

                 Type 3 Tests of Fixed Effects
 
                            Num     Den
   Effect                    DF      DF    F Value    Pr > F

   BASE                       1      12       0.43    0.5259
   trtn2                      0                             
   wk12                       0                             
   SSNRISN1                   1    12.9       0.09    0.7676
   VISITTYN1                  0                             
   BASE*wk12                  1      13       0.00    0.9830
   trtn2*VISITTYN1            0                             
   trtn2*wk12                 0                             
   wk12*VISITTYN1             0                             
   trtn2*wk12*VISITTYN1       0                             


 
 
 
 
^S={}CAPS-5: Clinician Administered PTSD Scale; CAPS-5 total sco
^S={}Note:The Modified Full Analysis Set includes all participan
^S={}Note: The baseline (Day -1) value is generally defined as t
^S={}Note:The CAPS-5 total score is the sum of the 20 item-score
^S={}Note: All ICEs are addressed using the treatment policy str
^S={}Note: The LS means, SEs,LS Mean Diff, 95% (CI) and p-value 
^S={}Note: The randomization stratification factor will be remov
^S={}PROGRAM NAME: C:\SASData\JZP-150\150-201\stat\csr_dryrun1\p
^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Jazz Pharmace
^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Protocol 150-
^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Table 9.2.1.3
^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Primary Effic
^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}(Modified Ful

                      The Mixed Procedure

                           Estimates
 
                               Standard
Label                Estimate     Error    DF  t Value  Pr > |t|

1 ACT-PBO    Week 4    6.0318    6.6668  12.2     0.90    0.3831
2 ACT-PBO  Week 4     Non-est                                   
1 ACT-PBO  Week 12     1.0399    5.7213    13     0.18    0.8586
2 ACT-PBO  Week 12    Non-est                                   

                           Estimates
 
      Label                 Alpha       Lower       Upper

      1 ACT-PBO    Week 4    0.05     -8.4622     20.5259
      2 ACT-PBO  Week 4                                  
      1 ACT-PBO  Week 12     0.05    -11.3229     13.4028
      2 ACT-PBO  Week 12                                 
 
 
 
^S={}CAPS-5: Clinician Administered PTSD Scale; CAPS-5 total sco
^S={}Note:The Modified Full Analysis Set includes all participan
^S={}Note: The baseline (Day -1) value is generally defined as t
^S={}Note:The CAPS-5 total score is the sum of the 20 item-score
^S={}Note: All ICEs are addressed using the treatment policy str
^S={}Note: The LS means, SEs,LS Mean Diff, 95% (CI) and p-value 
^S={}Note: The randomization stratification factor will be remov
^S={}PROGRAM NAME: C:\SASData\JZP-150\150-201\stat\csr_dryrun1\p
^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Jazz Pharmace
^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Protocol 150-
^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Table 9.2.1.3
^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Primary Effic
^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}(Modified Ful

                      The Mixed Procedure

                           Contrasts
 
                                           Num    Den
 Label                                      DF     DF   F Value

 Treatment*Week 4*Subgroup Interaction                         
 Treatment*Week 12*Subgroup Interaction                        

                           Contrasts
 
        Label                                    Pr > F

        Treatment*Week 4*Subgroup Interaction          
        Treatment*Week 12*Subgroup Interaction         
 
 
 
 
 
 
 
^S={}CAPS-5: Clinician Administered PTSD Scale; CAPS-5 total sco
^S={}Note:The Modified Full Analysis Set includes all participan
^S={}Note: The baseline (Day -1) value is generally defined as t
^S={}Note:The CAPS-5 total score is the sum of the 20 item-score
^S={}Note: All ICEs are addressed using the treatment policy str
^S={}Note: The LS means, SEs,LS Mean Diff, 95% (CI) and p-value 
^S={}Note: The randomization stratification factor will be remov
^S={}PROGRAM NAME: C:\SASData\JZP-150\150-201\stat\csr_dryrun1\p
